Bone allografts are widely being used in clinical practice for bone reconstruction. They are considered to be the most preferred alternative to bone autografts, mainly due to their availability and the elimination of donor site morbidity. The risk of bacterial and viral disease transmission, albeit low, is one of the major concerns associated with bone allograft transplant. This review focuses on the epidemiologic and microbiologic aspects of bone allograft infections and the current prevention and treatment options. It also discusses the role of the regulatory authorities in ensuring the safety and efficacy of bone allografts.